GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
N

Nfl Biosciences SAS ALNFL.PA · EUR

Health Care · Euronext Paris · 🇫🇷 France

Compare

0.39

+11.92%

Close of 9 Nov 2026, in EUR

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in EUR, from our data supplier.

FY2025

Revenue

—

FY2019FY2025

Net income

−€3.3m

FY2019FY2025

Free cash flow

—

FY2019FY2025

Shareholders' equity

€306,143

FY2019FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue—€46€200,011—€39€3—
Gross profit−€2.5m−€67,143−€56,064−€2.2m−€530,733−€169,359−€253,872
Operating income−€3.9m−€2.8m−€4.4m−€3.0m−€901,867−€318,028−€347,296
Net income−€3.3m−€2.1m−€3.7m−€2.4m−€978,244−€266,486−€267,960
Diluted earnings per share-0.26-0.21-0.46-0.47-0.19-0.02-0.02

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Total assets€3.7m€3.6m€4.0m€2.4m€3.7m€576,638€466,991
Cash and short-term investments€2.2m€2.1m€2.5m€1.2m€3.2m€310,201€224,933
Total liabilities€3.4m€2.6m€3.6m€1.6m€397,726€426,613€55,466
Debt€582,585€40,975€62,174€83,256€170,007€85,000—
Shareholders' equity€306,143€976,430€349,945€843,997€3.3m€150,025€411,525
Shares outstanding13m10m8m5m5m13m13m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash from operations———€104,888€87,000€83,914—
Free cash flow———€104,888€87,000€83,914—

Latest quarters

By quarter end

Jun 2026Dec 2025Jun 2025Dec 2024Jun 2024Dec 2023Jun 2023Dec 2022
Gross profit—−€2.5m−€40,917−€41,230−€25,913−€27,307−€28,757−€26,709
Operating income−€2.0m−€1.8m−€2.1m−€1.9m−€896,065−€2.0m−€2.5m−€1.7m
Net income−€1.5m−€1.5m−€1.8m−€1.3m−€731,509−€1.6m−€2.1m−€1.4m
Diluted earnings per share-0.12-0.12-0.14-0.14-0.07-0.20-0.26-0.26
Total assets—€3.7m€4.4m€3.6m€5.0m€4.0m€5.6m€2.4m
Cash and short-term investments—€2.2m€3.1m€2.1m€3.7m€2.5m€3.6m€1.2m
Debt—€582,585€30,330€81,950€23,026€22,971€145,454€166,505
Shareholders' equity—€306,143€1.8m€976,430€2.3m€349,945€1.9m€843,997

Growth per year

Compound annual rate

3 years5 years10 years
Operating income8.7%64.9%—
Net income10.7%65.6%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021
Price to earnings-4.5-9.3-3.1-4.2-12.8
Price to sales——58.4——

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.